➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
McKesson
Boehringer Ingelheim
Johnson and Johnson
Mallinckrodt

Last Updated: October 24, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,298,580


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,298,580 protect, and when does it expire?

Patent 8,298,580 protects TROKENDI XR and is included in one NDA.

This patent has eleven patent family members in eight countries.

Summary for Patent: 8,298,580
Title:Sustained-release formulations of topiramate
Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.
Inventor(s): Liang; Likan (Boyds, MD), Wang; Hua (Clarksville, MD), Bhatt; Padmanabh P. (Rockville, MD), Vieira; Michael L. (Gaithersburg, MD)
Assignee: Supernus Pharmaceuticals, Inc. (Rockville, MD)
Application Number:12/926,931
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,298,580
Patent Claim Types:
see list of patent claims
Formulation; Compound; Composition; Dosage form; Use;

Drugs Protected by US Patent 8,298,580

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-001 Aug 16, 2013 AB1 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE ⤷  Free Forever Trial
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-001 Aug 16, 2013 AB1 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y TREATMENT OF EPILEPSY ⤷  Free Forever Trial
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-002 Aug 16, 2013 AB1 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y TREATMENT OF EPILEPSY ⤷  Free Forever Trial
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-002 Aug 16, 2013 AB1 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,298,580

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2007319141 ⤷  Free Forever Trial
Canada 2618240 ⤷  Free Forever Trial
Germany 07870164 ⤷  Free Forever Trial
European Patent Office 1973528 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Merck
Dow
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.